tirzepatide chronic kidney disease trial Renal effects of GLP-1 receptor agonists and in individuals with type 2 diabetes: seeds of a promising future | Endocrine Tirzepatide and prevention of chronic

Monoclonal anti-BrdU (clone G3G4) and anti-desmin Abs (clone D3) were purchased from Developmental Studies Hybridoma Bank (Iowa City, IA, USA)

'Osteocytes, mature bone cells that help maintain bone structure and health, sense load and tell your body to make more bone as necessary

Treatment with liraglutide was started at age 21 years

Understanding Tirzepatide: What It Is: Dual GIP/GLP-1 receptor agonist First-in-class medication combining two mechanisms Activates both GIP and GLP-1 receptors Produces superior weight loss to single-agonist medications Half-life of approximately 5 days (allows once-weekly dosing) Brand Names: Zepbound: Indication: Chronic weight management in adults with obesity or overweight with comorbidities FDA Approval: November 2023 Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly) Manufacturer: Eli Lilly Cost: $1,069/month Mounjaro: Indication: Type 2 diabetes management FDA Approval: May 2022 Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly) Manufacturer: Eli Lilly Cost: $1,069/month Note: Identical to Zepbound, prescribed off-label for weight loss Compounded Tirzepatide: Source: FDA-registered compounding pharmacies Indication: Prescribed for weight loss by licensed providers Doses: Custom concentrations available Cost: $349-$699/month Same active ingredient as Zepbound/Mounjaro Why Tirzepatide Is More Effective: Dual Mechanism: GLP-1 Effects (Same as Semaglutide): Appetite suppression through brain receptors Slowed gastric emptying Increased insulin secretion Decreased glucagon production Additional GIP Effects: Enhanced insulin response beyond GLP-1 alone Improved insulin sensitivity in tissues Effects on fat metabolism and energy expenditure Synergistic appetite reduction Additional weight loss mechanisms Result: The combination produces 5-7% more weight loss than GLP-1 agonists alone

PMCID: PMC5632578

Introduction If you have been following the news in the UK lately, you will have undoubtedly heard of the "weight loss jab." Medications containing semaglutidemarketed under brand names such as Ozempic and Wegovyhave transformed the landscape of metabolic health and weight management